Gilles Brisson
Director/Board Member chez INNATE PHARMA
Fortune : 172 405 $ au 31/03/2024
Profil
Gilles Brisson currently works at Laboratoire Français du Fractionnement et des Biotechnologies, as Director, Innate Pharma SA, as Member-Supervisory Board from 2016, and Financière Verdi Iii, as Member-Supervisory Board from 2018.
Mr. Brisson also formerly worked at Ethypharm SAS, as Chairman-Supervisory Board from 2009 to 2016, Aventis Pharma SARL, as Chairman-Supervisory Board, Mauna Kea Technologies SA, as Chairman from 2012 to 2014, Bioring SA, as Chairman, Mutabilis Holding SAS, as Chairman, Grupo Carso SAB de CV, as Member-Supervisory Board, Sanofi-Aventis Europe SAS, as SVP-European Commercial Operations, and Rhone Poulenc Rorer, as Senior Vice President-Corporate Development.
Mr. Brisson received his undergraduate degree from École des Hautes Études Commerciales de Paris.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INNATE PHARMA SA CLASS A
0,09% | 31/12/2022 | 73 059 ( 0,09% ) | 172 405 $ | 31/03/2024 |
Postes actifs de Gilles Brisson
| Sociétés | Poste | Début |
|---|---|---|
| INNATE PHARMA | Director/Board Member | 30/12/2016 |
Laboratoire Français du Fractionnement et des Biotechnologies
 Laboratoire Français du Fractionnement et des Biotechnologies BiotechnologyHealth Technology Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France. | Director/Board Member | - |
Financière Verdi Iii
 Financière Verdi Iii Financial ConglomeratesFinance Financière Verdi III is an investment holding private company based in Paris, France. The French company functions as an investment holding company. | Director/Board Member | 01/07/2018 |
Anciens postes connus de Gilles Brisson
| Sociétés | Poste | Fin |
|---|---|---|
Ethypharm SAS
 Ethypharm SAS Pharmaceuticals: MajorHealth Technology Ethypharm SAS is a holding company, which engages in developing pharmaceutical products. It offers treatment for pain and addiction, as well as complex generic drugs. The company was founded by G?rard Leduc and Patrice Debregreas in 1977 and is headquartered in Saint-Cloud, France. | Chairman | 06/08/2016 |
| MAUNA KEA TECHNOLOGIES | Chairman | 11/06/2014 |
Bioring SA
 Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | Chairman | 05/04/2013 |
| GRUPO CARSO, S.A.B. DE C.V. | Director/Board Member | - |
| Mutabilis Holding SAS | Chairman | - |
Formation de Gilles Brisson
| École des Hautes Études Commerciales de Paris | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GRUPO CARSO, S.A.B. DE C.V. | Retail Trade |
| INNATE PHARMA | Health Technology |
| MAUNA KEA TECHNOLOGIES | Health Technology |
| Entreprise privées | 8 |
|---|---|
Sanofi-Aventis Europe SAS
 Sanofi-Aventis Europe SAS Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Aventis Europe SAS is a pharmaceutical company based in Paris, France. The French company manufactures pharmaceuticals. The CEO of the private company is Jérôme Contamine. | Health Technology |
Ethypharm SAS
Ethypharm SAS Pharmaceuticals: MajorHealth Technology Ethypharm SAS is a holding company, which engages in developing pharmaceutical products. It offers treatment for pain and addiction, as well as complex generic drugs. The company was founded by G?rard Leduc and Patrice Debregreas in 1977 and is headquartered in Saint-Cloud, France. | Health Technology |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Process Industries |
Aventis Pharma SARL
 Aventis Pharma SARL Pharmaceuticals: MajorHealth Technology Founded in 1982, Aventis Pharma SARL is a French pharmaceutical company that manufactures pharmaceuticals. Part of Sanofi, the private company is based in Antony, France. | Health Technology |
Laboratoire Français du Fractionnement et des Biotechnologies
Laboratoire Français du Fractionnement et des Biotechnologies BiotechnologyHealth Technology Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France. | Health Technology |
Bioring SA
Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | Health Technology |
| Mutabilis Holding SAS | |
Financière Verdi Iii
Financière Verdi Iii Financial ConglomeratesFinance Financière Verdi III is an investment holding private company based in Paris, France. The French company functions as an investment holding company. | Finance |
